XTLB (XTL Biopharmaceuticals) Total Current Assets: $0.53 Mil (As of Jun. 2025)


XTLB XTL Biopharmaceuticals Ltd XTLB
26 GF Score
Price $2.49
! 2 Warning Signs
View Full Analysis

What is XTL Biopharmaceuticals Total Current Assets?

XTL Biopharmaceuticals XTLB +5.30% 26 Total Current Assets is $0.53 Mil as of Jun. 2025. GuruFocus rates XTLB with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. XTL Biopharmaceuticals's total current assets for the quarter that ended in Jun. 2025 was $0.53 Mil.

XTL Biopharmaceuticals  (NAS:XTLB) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

XTL Biopharmaceuticals's Liquidation Value for the quarter that ended in Jun. 2025 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=0.259-0.761+0.75 * 0.09+0.5 * 0
=-0.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XTL Biopharmaceuticals Total Current Assets Related Terms

XTL Biopharmaceuticals Total Current Assets Historical Data

* Premium members only.

The historical data trend for XTL Biopharmaceuticals's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XTL Biopharmaceuticals Total Current Assets Chart

XTL Biopharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.12 6.24 3.81 2.05 1.34

XTL Biopharmaceuticals Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.50 2.05 2.02 1.34 0.53
XTLB
26GF Score
XTL Biopharmaceuticals Ltd XTLB
Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XTL Biopharmaceuticals Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

XTL Biopharmaceuticals's Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=1.143+0.15+0+0.047
=1.34

XTL Biopharmaceuticals's Total Current Assets for the quarter that ended in Jun. 2025 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=0.259+0.09+0+0.184
=0.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of $0.53 Mil mean?
XTL Biopharmaceuticals (XTLB) has a Total Current Assets of $0.53 Mil as of Jun. 2025. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for XTL Biopharmaceuticals and its competitors.
Is XTL Biopharmaceuticals' Total Current Assets too high?
XTL Biopharmaceuticals' current Total Current Assets is $0.53 Mil. Overall, XTL Biopharmaceuticals has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does XTL Biopharmaceuticals' Total Current Assets compare to VRTX and REGN?
XTL Biopharmaceuticals' Total Current Assets of $0.53 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Biotechnology company?
A good Total Current Assets depends on the Biotechnology industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for XTL Biopharmaceuticals and its competitors. XTL Biopharmaceuticals's current Total Current Assets is $0.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XTL Biopharmaceuticals stock overvalued right now?
XTL Biopharmaceuticals (XTLB) has a current Total Current Assets of $0.53 Mil. The current Total Current Assets is $0.53 Mil. XTL Biopharmaceuticals' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For XTL Biopharmaceuticals (XTLB), the current Total Current Assets is $0.53 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

XTL Biopharmaceuticals Business Description

Other Exchanges XTLB:IsraelHHB0:Germany
Address 26 Ben-Gurion Street, Ramat Gan, ISR, 5112001
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
26GF Score

Get the complete analysis for XTLB

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.49
Price